Back

Clinical impact of more than 50% reduction in low-density lipoprotein cholesterol at 6 weeks after percutaneous coronary intervention for acute coronary syndrome

29 August 2026 (08:15 - 09:00)
Organised by: Logo
Congress Presentation Part of: Lipoproteins and coronary artery disease (1) Lipids ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Kota Murai

National Cerebral and Cardiovascular Center Hospital, Osaka (Japan)

5 More presentations in this session

Presentation thumbnail
Prevalence and impact of a pathogenic CYP27A1 variant on phenotypes among patients with monogenic heterozygous familial hypercholesterolemia
Doctor H. Tada (Kanazawa, JP)
Abstract Slides
Presentation thumbnail
Apolipoprotein b discordance at very low low-density lipoprotein cholesterol thresholds: a patient-level analysis
Doctor J. Bernhard (Vienna, AT)
Abstract Slides
Presentation thumbnail
Nationwide genotypic and phenotypic characterisation of homozygous familial hypercholesterolemia
Doctor C. Lin (Taipei, TW)
Abstract Slides
Presentation thumbnail
Prevalence of elevated lipoprotein(a) [Lp(a)] in patients with familial hypercholesterolemia (FH)
Doctor J. Sawhney (New Delhi, IN)
Abstract Slides
Presentation thumbnail
Lipoprotein(a) lowering and risk of cardiovascular disease in primary and secondary prevention
Mr P. Kamstrup (Copenhagen, DK)
Abstract Slides

Access the full session

Session thumbnail
Lipoproteins and coronary artery disease (1)

The Event

Event poster

ESC Congress 2026

29 August 2026 08:15 CET
You may be interested in
thumbnail
Congress Presentation
LDL-cholesterol levels post-acute coronary syndrome: 24-months variation
4 April 2025
thumbnail
Congress Presentation
Modelling the long-term clinical outcomes of AI-enabled CCTA plaque quantification on preventive cardiovascular management
4 April 2025
thumbnail
Congress Presentation
Evidence- and experience-based strategies of rapid LDL reduction in ACS.
18 March 2022
thumbnail
Congress Presentation
LDL-C reduction and residual cardiovascular risk in heterozygous familial hypercholesterolemia: a matched cohort study in South Wales
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources